NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
PDQ Cancer Information Summaries [Internet].
Show detailsThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood pulmonary inflammatory myofibroblastic tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.
This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Incidence and Histology
Inflammatory myofibroblastic tumors (IMTs) occur throughout the body, but the lungs are the most commonly involved organs. IMTs are one of the most frequent lung tumors in children, accounting for between 16% and 38% of cases in various series.[1-3]
The biology of IMT is variable, with the potential for local recurrences and rare distant metastases.[4] The ALK locus (located on chromosome 2p23) is rearranged in approximately 50% of IMT cases. ALK rearrangements can involve various different genes.[5,6] Other potentially targetable fusions have been reported in a smaller fraction of IMTs, including ROS1, NTRK3, RET, and PDGFRB fusions.[6,7]
References
- Yu DC, Grabowski MJ, Kozakewich HP, et al.: Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg 45 (6): 1090-5, 2010. [PubMed: 20620301]
- Weldon CB, Shamberger RC: Pediatric pulmonary tumors: primary and metastatic. Semin Pediatr Surg 17 (1): 17-29, 2008. [PubMed: 18158138]
- Siemion K, Reszec-Gielazyn J, Kisluk J, et al.: What do we know about inflammatory myofibroblastic tumors? - A systematic review. Adv Med Sci 67 (1): 129-138, 2022. [PubMed: 35219201]
- Lichtenberger JP, Biko DM, Carter BW, et al.: Primary Lung Tumors in Children: Radiologic-Pathologic Correlation From the Radiologic Pathology Archives. Radiographics 38 (7): 2151-2172, 2018 Nov-Dec. [PubMed: 30422774]
- Coffin CM, Hornick JL, Fletcher CD: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31 (4): 509-20, 2007. [PubMed: 17414097]
- Lovly CM, Gupta A, Lipson D, et al.: Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4 (8): 889-95, 2014. [PMC free article: PMC4125481] [PubMed: 24875859]
- Antonescu CR, Suurmeijer AJ, Zhang L, et al.: Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 39 (7): 957-67, 2015. [PMC free article: PMC4465992] [PubMed: 25723109]
Clinical Presentation and Diagnostic Evaluation
Inflammatory myofibroblastic tumors (IMTs) present with a large, peripherally located lobulated mass with a lower lobe predominance. Chest wall, vascular, and mediastinal invasion may be seen. Calcification is occasionally present. Enhancement is heterogeneous on contrast-enhanced computed tomography. Magnetic resonance imaging findings are variable, but IMTs may be isointense relative to skeletal muscle.
Treatment of Childhood Pulmonary Inflammatory Myofibroblastic Tumors
Treatment options for pulmonary inflammatory myofibroblastic tumors (IMTs) include the following:[1-3]
Surgery
If possible, surgical resection is the treatment of choice. Patients with completely resected tumors have an excellent prognosis.
Targeted therapy
Patients with unresectable or recurrent tumors may respond to crizotinib if the ALK variant is present and crizotinib administration is followed by complete or incomplete resection. Treatment with ceritinib and entrectinib have also produced objective responses.
Evidence (targeted therapy):
- Crizotinib.
- One study included 14 patients with IMTs who were treated with crizotinib.[4][Level of evidence C3]
- Five patients had complete responses, seven patients had partial responses, and the remaining two patients had stable disease.
- No patients experienced a relapse when this article was published.
- An extensive review confirmed that crizotinib was effective in children who had IMTs (with various tumor sites).[5]
The U.S. Food and Drug Administration (FDA) approved crizotinib for use in patients aged 1 year and older with unresectable, recurrent, or refractory ALK-positive IMTs. - Ceritinib. In a multicenter phase I study, seven of ten patients with IMTs had objective responses to ceritinib.[6]
- Entrectinib. In a phase I/II study of entrectinib, two patients with IMTs and ALK fusions experienced a complete response and a partial response, respectively.[7]
For more information about the treatment of this tumor, see the Inflammatory myofibroblastic tumor and epithelioid inflammatory myofibroblastic sarcoma section in Childhood Soft Tissue Sarcoma Treatment.
References
- Coffin CM, Hornick JL, Fletcher CD: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31 (4): 509-20, 2007. [PubMed: 17414097]
- Butrynski JE, D'Adamo DR, Hornick JL, et al.: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363 (18): 1727-33, 2010. [PMC free article: PMC3014292] [PubMed: 20979472]
- Chavez C, Hoffman MA: Complete remission of ALK-negative plasma cell granuloma (inflammatory myofibroblastic tumor) of the lung induced by celecoxib: A case report and review of the literature. Oncol Lett 5 (5): 1672-1676, 2013. [PMC free article: PMC3678867] [PubMed: 23761833]
- Mossé YP, Voss SD, Lim MS, et al.: Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol 35 (28): 3215-3221, 2017. [PMC free article: PMC5617123] [PubMed: 28787259]
- Nakano K: Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy. Jpn J Clin Oncol 53 (10): 885-892, 2023. [PubMed: 37394916]
- Fischer M, Moreno L, Ziegler DS, et al.: Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol 22 (12): 1764-1776, 2021. [PubMed: 34780709]
- Desai AV, Robinson GW, Gauvain K, et al.: Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol 24 (10): 1776-1789, 2022. [PMC free article: PMC9527518] [PubMed: 35395680]
Treatment Options Under Clinical Evaluation for Childhood Pulmonary Inflammatory Myofibroblastic Tumors
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Special Considerations for the Treatment of Children With Cancer
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
- Primary care physicians.
- Pediatric surgeons.
- Pathologists.
- Pediatric radiation oncologists.
- Pediatric medical oncologists and hematologists.
- Ophthalmologists.
- Rehabilitation specialists.
- Pediatric oncology nurses.
- Social workers.
- Child-life professionals.
- Psychologists.
- Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
- A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
- The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4]Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
References
- Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. [PMC free article: PMC2881732] [PubMed: 20404250]
- American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics 134 (2): 410-4, 2014. Also available online. Last accessed August 23, 2024.
- Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. [PMC free article: PMC4136455] [PubMed: 24853691]
- National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. Available online. Last accessed August 23, 2024.
- Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. Bethesda, MD: National Cancer Institute. Available online. Last accessed September 5, 2024.
- Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr. [PubMed: 24488779]
- Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017. [PubMed: 28687376]
- DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017. [PubMed: 28542893]
- Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019. [PubMed: 30785015]
- Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010. [PMC free article: PMC3020699] [PubMed: 20956621]
Latest Updates to This Summary (08/07/2024)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This summary was comprehensively reviewed.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® Cancer Information for Health Professionals pages.
About This PDQ Summary
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood pulmonary inflammatory myofibroblastic tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment are:
- Denise Adams, MD (Children's Hospital Boston)
- Karen J. Marcus, MD, FACR (Dana-Farber Cancer Institute/Boston Children's Hospital)
- William H. Meyer, MD
- Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)
- Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)
- Alberto S. Pappo, MD (St. Jude Children's Research Hospital)
- Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)
- Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)
- Stephen J. Shochat, MD (St. Jude Children's Research Hospital)
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
The preferred citation for this PDQ summary is:
PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/lung/hp/child-pulmonary-inflammatory-myofibroblastic-tumor-treatment-pdq. Accessed <MM/DD/YYYY>. [PMID: 35412727]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
Disclaimer
Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
Contact Us
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.
- Incidence and Histology
- Clinical Presentation and Diagnostic Evaluation
- Treatment of Childhood Pulmonary Inflammatory Myofibroblastic Tumors
- Treatment Options Under Clinical Evaluation for Childhood Pulmonary Inflammatory Myofibroblastic Tumors
- Special Considerations for the Treatment of Children With Cancer
- Latest Updates to This Summary (08/07/2024)
- About This PDQ Summary
- Review Childhood Tracheobronchial Tumors Treatment (PDQ®): Health Professional Version.[PDQ Cancer Information Summari...]Review Childhood Tracheobronchial Tumors Treatment (PDQ®): Health Professional Version.PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002
- Review Childhood Cardiac Tumors Treatment (PDQ®): Health Professional Version.[PDQ Cancer Information Summari...]Review Childhood Cardiac Tumors Treatment (PDQ®): Health Professional Version.PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002
- Review Childhood Breast Tumors Treatment (PDQ®): Health Professional Version.[PDQ Cancer Information Summari...]Review Childhood Breast Tumors Treatment (PDQ®): Health Professional Version.PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002
- Review Childhood Laryngeal Tumors Treatment (PDQ®): Health Professional Version.[PDQ Cancer Information Summari...]Review Childhood Laryngeal Tumors Treatment (PDQ®): Health Professional Version.PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002
- Review Childhood Salivary Gland Tumors Treatment (PDQ®): Health Professional Version.[PDQ Cancer Information Summari...]Review Childhood Salivary Gland Tumors Treatment (PDQ®): Health Professional Version.PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002
- Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment (PDQ®) - PDQ C...Childhood Pulmonary Inflammatory Myofibroblastic Tumors Treatment (PDQ®) - PDQ Cancer Information Summaries
- Oropharyngeal Cancer Treatment (PDQ®) - PDQ Cancer Information SummariesOropharyngeal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries
- tight junction protein ZO-2-like isoform X2 [Siniperca chuatsi]tight junction protein ZO-2-like isoform X2 [Siniperca chuatsi]gi|2108558958|ref|XP_044053726.1|Protein
- Childhood Pleuropulmonary Blastoma Treatment (PDQ®) - PDQ Cancer Information Sum...Childhood Pleuropulmonary Blastoma Treatment (PDQ®) - PDQ Cancer Information Summaries
- Esophageal Cancer Screening (PDQ®) - PDQ Cancer Information SummariesEsophageal Cancer Screening (PDQ®) - PDQ Cancer Information Summaries
Your browsing activity is empty.
Activity recording is turned off.
See more...